论文部分内容阅读
目的研究不同情况下血清低密度脂蛋白(LDL)水平的变化,观察洛伐他汀调血脂治疗高脂血症患者LDL的影响。方法采用非变型梯度凝胶电泳法分别测定37例冠脉正常的高脂血症患者、56例冠脉造影证实有冠心病的高脂血症患者及40例冠脉及血脂均正常的受检者LDL的水平,比较三组间LDL水平的差异;另外测定25例高胆固醇血症,32例混合型高脂血症和32例高甘油三酯血症患者的LDL水平,与40例冠脉及血脂均正常的受检者对比,并对甲、乙两组患者进行洛伐他汀调血脂治疗8周,然后再次取血测定LDL的水平。结果与正常受检者相比,冠脉正常的高脂血症患者LDL的含量仅有轻度升高(52.4±13.5%vs48.6±6.3%,P>0.05),但合并冠心病的高脂血症患者LDL的含量明显升高(64.3±18.4%vs48.6±6.3%,P<0.01)。不同类型的高脂血症患者血清LDL含量均较正常者为高,其中以混合型高脂血症(66.9±10.2%vs48.6±6.3%,P<0.01)和高甘油三酯(69.5±13.4%vs48.6±6.3%,P<0.01)患者升高最为明显。洛伐他汀治疗8周后,这两组患者LDL的含量分别由65.7±11.9%降至55.6±8.7%(P<0.05),67.8±10.5%降至52.8±9.3%(P<0.05)。结论合并有冠心病的高脂血症患者LDL的升高更为明显,不同类型的高脂血症患者LDL均表现为升高,洛伐他汀可显著降低高脂血症患者血清LDL的含量。
Objective To study the changes of serum low density lipoprotein (LDL) levels under different conditions and to observe the effect of lovastatin on blood lipids in patients with hyperlipidemia. Methods 37 cases of hyperlipidemia with normal coronary artery were measured by non-modified gradient gel electrophoresis. Fifty-six patients with hyperlipemia who had coronary heart disease and 40 patients with coronary artery and lipids were confirmed by coronary angiography. LDL levels were compared between the three groups LDL levels were compared; In addition to the determination of 25 cases of hypercholesterolemia, 32 cases of mixed hyperlipidemia and 32 cases of hypertriglyceridemia in patients with LDL levels, and 40 cases of coronary artery And blood lipids were normal subject comparison, and A, B two groups of patients with lovastatin lipid-lowering therapy for 8 weeks, and then take blood again to determine the level of LDL. Results Compared with normal subjects, LDL levels in patients with normal coronary hyperlipidemia were only slightly elevated (52.4 ± 13.5% vs 48.6 ± 6.3%, P> 0.05), but the high coronary heart disease The level of LDL was significantly higher in patients with lipidemia (64.3 ± 18.4% vs 48.6 ± 6.3%, P <0.01). The levels of serum LDL in patients with different types of hyperlipidemia were higher than those in normal subjects. Among them, hyperlipidemia (66.9 ± 10.2% vs 48.6 ± 6.3%, P <0.01) and high triglyceride (69.5 ± 13.4% vs48.6 ± 6.3%, P <0.01) in patients with the most obvious increase. After 8 weeks of lovastatin treatment, the levels of LDL decreased from 65.7 ± 11.9% to 55.6 ± 8.7% (P <0.05) and from 67.8 ± 10.5% to 52.8 ± 9.3% (P <0.05) respectively. Conclusions Patients with hyperlipidemia complicated with coronary heart disease have more obvious increase of LDL. LDL of patients with different types of hyperlipidemia show an increase, and lovastatin can significantly reduce the serum LDL of patients with hyperlipidemia.